Specify a stock or a cryptocurrency in the search bar to get a summary
ADMA Biologics Inc
ADMAADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey. Address: 465 State Route 17, Ramsey, NJ, United States, 07446
Analytics
WallStreet Target Price
19 USDP/E ratio
123.6429Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ADMA
Dividend Analytics ADMA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ADMA
Stock Valuation ADMA
Financials ADMA
Results | 2019 | Dynamics |